Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA_seq and Ribo_seq analyses applied to PC9 and H1933 human cancer cell lines

ABSTRACT: We used RNA-seq and Ribo-seq analyses to examine translation efficiency (TE) in PC9 and H1933 cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE96716 | GEO | 2017/06/13

SECONDARY ACCESSION(S): PRJNA379447

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA_seq and Ribo_seq analyses of control and CPT-treated MCF7 cells

Project description:We used RNA-seq and Ribo-seq analyses to examine the effect of CPT treatment of translation efficiency (TE)

2017-04-01 | GSE96643 | GEO

RNA_seq and Ribo_seq analyses of control and Nutlin3a-treated MCF7 cells (20 hrs)

Project description:We used RNA-seq and Ribo-seq analyses to examine the effect of Nutlin3a (activator of p53) treatment of translation efficiency (TE)

2017-06-13 | GSE96714 | GEO

Gene expression of PC9 and PC9-OR cell line [JXQ_RNA]

Project description:To investigate the abnormal gene expression in Osimertinib Resistance lung cancer cell line, We performed gene expression profiling analysis using data obtained from RNA-seq of PC9 cell line and PC9-OR cell line.

2024-03-13 | GSE222820 | GEO

Mutational analysis of PC9 and PC9-OR cell lines. [JXQ_WES]

Project description:Mutational analysis of PC9 and PC9-OR cell lines. [JXQ_WES]

| PRJNA924693 | ENA

Transcriptome analysis of PC9 cells with gefitinib or/and hypoxia treatment and comparison with gefitinib resistant PC9 cells and ALDH positive PC9 cells

Project description:Inevitable gefitinib resistance and relapse of the disease was the biggest hurdle to NSCLC treatment. Importantly, the role of hypoxia in solid tumor tissues in vivo in gefitinib acquired resistance and its relationship to lung cancer stem cells (LCSCs) has not been fully elucidated. Here, the PC9 cells were treated with short term gefitinib or/and hypoxia, also, PC9 gefitnib resistant (PC9-GR) cell line was established and ALDH positive PC9 cells were sorted by FACs. Transcriptome analysis among those PC9 cell groups revealed the important role of hypoxia in gefitinib acquired resistance and signaling transduction change, which may critical for NSCLC disease progression and recurrence.

2017-10-31 | GSE69599 | GEO

Ribo-seq of decitabine-treated WT HL-60 cells

Project description:Ribolog was used to compare translational efficiency across conditions (https://github.com/goodarzilab/Ribolog). Briefly, Ribolog applies a logistic regression to model individual Ribo-seq and RNA-seq reads in order to provide estimates of logTER (i.e., logFC in TE) and its associated p-value across the coding transcriptome.

2023-01-13 | GSE222825 | GEO

Differential expression genes between PC9 cells and osimertinib resistant PC9OR cells

Project description:To investigate the possible resistant mechanism to osimertinib, PC9 cells and their derived osimertinib-resistant PC9OR cells were sequenced using illumina HiSeq. We then performed gene expression profiling analysis using data obtained from RNA-seq of PC9 cells and their derived PC9OR cells.

2022-11-02 | GSE201549 | GEO

Next generation sequencing facilitates quantitative analysis of PC9 and MTAC-P (EGFR-TKI resistant cell line derived from PC9)

Project description:The goals of this study are to compare the different transcriptome signiture between PC9 and MTAC-P with NGS-derived retinal transcriptome profiling (RNA-seq).

2019-10-29 | GSE79763 | GEO

Gene expression profiling of erlotinib-resistant PC9 cells.

Project description:The non-small cell lung carcinoma (NSCLC) PC9 cell line is an established preclinical model for tyrosine kinase inhibitors. To better understand gene expression changes in cells that survived the inhibitor treatment, we treated the EGFR-mutant PC9 cells with erlotinib, isolated RNA, and performed RNA-seq analysis. We were able to identify genes that are differentially expressed in erlotinib-treated cells compared to untreated. The results of this study will be integrated with single cell RNA-seq to address the utility of bulk RNA versus single cell RNA strategies in identifying biomarkers of drug resistance.

2020-12-19 | GSE148465 | GEO

Genome wide H3k27ac modification changes in Wild Type PC9 cells and MED13L knocking-down PC9 cells [H3K27ac ChIP-seq]

Project description:Silencing of MED13L impairs Mediator-regulated chromatin H3K27ac modification in NSCLC. Here, we performed H3K27ac ChIP-seq to investigate impacts of miR-4497 or knocking-down MED13L on chromatin H3K27ac modification in NSCLC PC9 cells.

2020-08-19 | GSE147120 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data